Contradictions Uncovered: Navigating NHC Leases, Incentives, and SHOP Growth Strategies in Q1 2025

None



Strong Start in 2025:
- National Health Investors, Inc. exceeded expectations in Q1 2025, with normalized FFO guidance midpoint raised by $0.08 per share to $4.71.
- The growth was driven by a faster pace of acquisitions and upside in cash rent collections.

Accelerated Deal Flow:
- The company has invested $174.9 million so far this year, with an active pipeline of $264 million and a potential for additional investments.
- The acceleration is attributed to an active seller market, a limited buyer pool, and NHI's competitive cost of capital.

SHOP Portfolio Growth:
- The SHOP portfolio's NOI increased 4.9% year-over-year to $3.1 million.
- Growth is expected to continue with plans to convert a six-property portfolio to a new partnership, and internal conversions are seen as a long-term value creator.

Dividend and Guidance Increase:
- National Health Investors increased its full year 2025 guidance for NAREIT FFO and normalized FFO by $0.04 and $0.08 respectively.
- Guidance includes assumptions for additional investments and a focus on maintaining strong cash flow to meet pipeline demands.

Financial Performance and Debt Management:
- Net income for diluted common shares was up 4.2% to $0.74, and NAREIT FFO increased 3.6% to $1.14.
- The financial performance is supported by a strong balance sheet, and the company plans to address debt maturities through equity offerings and long-term bond issuance.